Eosinophilic Granulomatous Vasculitis Clinical Trial
— MANDARAOfficial title:
A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study)
| Verified date | June 2024 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC (earlier enrolled patients may therefore be in the OLE for longer than 1 year).
| Status | Active, not recruiting |
| Enrollment | 140 |
| Est. completion date | March 31, 2026 |
| Est. primary completion date | August 10, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 130 Years |
| Eligibility | Inclusion Criteria: 1. Male or female subjects age 18 years or older. 2. EGPA diagnosis based on history or presence asthma and eosinophilia (>1.0x10^9/L and/or >10% of leucocytes) and at least 2 of; biopsy with eosinophilic vasculitis or perivascular/granulomatous inflammation; mono-or polyneuropathy, non-fixed pulmonary infiltrates, sino-nasal abnormality; cardiomyopathy; glomerulonephritis; alveolar haemorrhage; palpable purpura; anti neutrophil cytoplasmic anti-body (ANCA) positivity (Myeloperoxidase or proteinease 3). 3. History of relapsing (at least 1 confirmed EGPA relapse within last 2 years and > 12 weeks prior to screening), or refractory (failure to attain remission, defined as BVAS=0 and oral corticosteroid (OCS) dose <=7.5 mg/day of prednisolone or equivalent, following standard induction regimen for at least 3 months and within 6 months prior to screening, or recurrence of symptoms upon OCS tapering at any dose of =7.5 mg/day prednisolone or equivalent. If induction with glucocorticoidsalone, patient must have failed to attain remission after 3 months and the glucocorticoid dose must be =15 mg/day prednisolone or equivalent for the 4 weeks prior to randomization. 4. Must be on a stable dose of oral prednisolone or prednisone of =7.5 mg/day (but not >50mg/day) for at least 4 weeks prior to randomization. 5. If receiving immunosuppressive therapy (excluding cyclophosphamide) the dose must be stable for the 4 weeks prior to randomization and during the study (dose reductions for safety reasons will be permitted). 6. QTc(F)<450 msec or QTc(F)<480 msec for patients with bundle branch block. 7. Females of childbearing potential must use an acceptable method of birth control from randomization for at least 12 weeks after the last study drug administration. Exclusion Criteria: 1. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) 2. Organ or life-threatening EGPA < 3 months prior to screening 3. Currently pregnant or breastfeeding, or planning to become pregnant during study participation. 4. Current malignancy or history of malignancy, unless received curative therapy >5 years ago, or >1 year ago for basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix 5. An untreated or refractory helminth parasitic infection < 24 weeks prior to screening 6. Unstable liver disease 7. Severe or clinically significant, uncontrolled cardiovascular disease 8. Other concurrent disease that may put the patient at risk, or may influence the results of the study, or the patients' ability to complete entire duration of the study 9. Chronic or ongoing infectious disease requiring systemic anti-infective treatment 10. Known immunodeficiency disorder or positive HIV test 11. Prior receipt of mepolizumab, reslizumab, dupilumab or benralizumab. Receipt of intravenous/intramuscular/subcutaneous corticosteroids within 4 weeks prior to randomization, receipt of omalizumab within 130 days prior to screening, rituximab within 6 months prior to screening (or B-cells not recovered), interferon-a or alemtuzumab within 6 months prior to screening, receipt of anti-tumor necrosis factor therapy within 12 weeks prior to screening or an investigational non-biologic product within 30 days or 5 half-lives prior to screening, whichever is longer. Receipt of any other marketed or investigational biologic products within 4 months or 5 half-lives prior to screening, whichever is longer. |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | Research Site | Brussel | |
| Belgium | Research Site | Brussels | |
| Canada | Research Site | Calgary | Alberta |
| Canada | Research Site | Hamilton | Ontario |
| Canada | Research Site | Toronto | Ontario |
| Canada | Research Site | Toronto | Ontario |
| France | Research Site | Dijon Cedex | |
| France | Research Site | Marseille | |
| France | Research Site | Montpellier | |
| France | Research Site | Nantes Cedex 1 | |
| France | Research Site | Paris | |
| France | Research Site | Paris | |
| France | Research Site | Suresnes Cedex | |
| France | Research Site | Toulouse | |
| Germany | Research Site | Bamberg | |
| Germany | Research Site | Freiburg | |
| Germany | Research Site | Hamburg | |
| Germany | Research Site | Kirchheim | |
| Germany | Research Site | Lübeck | |
| Israel | Research Site | Ashkelon | |
| Israel | Research Site | Beer Sheva | |
| Israel | Research Site | Jerusalem | |
| Israel | Research Site | Ramat Gan | |
| Israel | Research Site | Rehovot | |
| Israel | Research Site | Tel Aviv | |
| Italy | Research Site | Cuneo | |
| Italy | Research Site | Firenze | |
| Italy | Research Site | Milano | |
| Italy | Research Site | Milano | |
| Italy | Research Site | Napoli | |
| Italy | Research Site | Roma | |
| Italy | Research Site | Torino | |
| Japan | Research Site | Chiba-shi | |
| Japan | Research Site | Kita-gun | |
| Japan | Research Site | Sagamihara-shi | |
| Japan | Research Site | Sendai-shi | |
| Japan | Research Site | Shinjuku-ku | |
| United Kingdom | Research Site | Cambridge | |
| United Kingdom | Research Site | Leicester | |
| United Kingdom | Research Site | London | |
| United Kingdom | Research Site | Portsmouth | |
| United States | Research Site | Albuquerque | New Mexico |
| United States | Research Site | Ann Arbor | Michigan |
| United States | Research Site | Denison | Texas |
| United States | Research Site | Denver | Colorado |
| United States | Research Site | Great Neck | New York |
| United States | Research Site | New York | New York |
| United States | Research Site | Philadelphia | Pennsylvania |
| United States | Research Site | Rochester | Minnesota |
| United States | Research Site | Seattle | Washington |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
United States, Belgium, Canada, France, Germany, Israel, Italy, Japan, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Numbers of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Minimum of 52 weeks | ||
| Primary | Proportion of patients who are in remission at both weeks 36 and 48 | Patients must be in remission at both of these timepoints of weeks 36 and 48.
Main definition: Remission is defined as BVAS=0 and OCS dose = 4mg/day. Supportive definition: Remission is defined by BVAS =0 and OCS dose = 7.5 mg/day. Analysis will be repeated based on main and supportive remission definitions. |
week 36 and week 48 | |
| Secondary | Number of patients in each category of accrued duration of remission | The categories of accrued duration of remission are: 0 wk, >0 to <12 wk, 12 to <24 wk, 24 to <36 wk, =36 wk. Analysis will be repeated based on main and supportive remission definitions. | Up to 52 weeks | |
| Secondary | Time from randomisation to first EGPA relapse | Relapse is defined as any of the following:
Active vasculitis (BVAS >0); OR Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions warranting any of the following: an increase of OCS therapy (>4mg prednisolone total daily dose or equivalent); an increased dose or addition of an immunosuppressive agent; Hospitalisation related to EGPA worsening. |
During first 52 weeks | |
| Secondary | Based on the average daily prednisolone/prednisone dose during Weeks 48 through 52: | Proportion of patients in each category of average daily prednisolone/prednisone dose during Weeks 48 through 52 using the following categories: 0 mg; > 0 to =4 mg; > 4 to = 7.5 mg and > 7.5 mg.
Proportion of patients in each category of percent reduction from baseline: no reduction or withdrawal from treatment; < 25% reduction; 25 to < 50% reduction; 50 to < 75% reduction; 75 to < 100% reduction; 100% reduction. Proportion of patients with = 50% reduction from baseline. Proportion of patients with 100% reduction from baseline. Proportion of patients with = 4 mg in average daily dose. |
week 48 through week 52 | |
| Secondary | Proportion of patients who have achieved any clinical benefit when meeting any of the criteria below. Proportion of patients who have achieved complete response when meeting all of the criteria below. | Remission (defined as BVAS = 0 and prednisolone/prednisone dose = 4 mg/day) at any time during the double-blind treatment period
= 50% reduction in average daily prednisolone/prednisone dose during Weeks 48 through 52 EGPA relapse free during the double-blind treatment period. Analysis will be repeated for the supportive remission definition. |
Up to 52 weeks | |
| Secondary | Annualized relapse rate | Over first 52 weeks | ||
| Secondary | Proportion of patients who have achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period | Analysis will be repeated based on main and supportive remission definitions. | Up to 52 weeks | |
| Secondary | Change from baseline in VDI | Vasculitis Damage Index (VDI)
Vasculitis Damage Index measures accrued damage across 11 organ systems since diagnosis. Total score is sum of all systems and ranges from 0 to 64 with higher scores indicating more damage. |
Up to 52 weeks | |
| Secondary | Change from baseline in BVAS | Birmingham Vasculitis Activity Score (BVAS)
Birmingham Vasculitis Activity Score (BVAS) measures vasculitis disease activity across 9 organ systems. Total score is sum of the weighted organ scores and ranges from 0 to 63 with higher scores indicating higher disease activity. |
Up to 52 weeks | |
| Secondary | Change from baseline in pulmonary function | As measured by Forced vital capacity (FVC) and Forced Expiratory Volume during first second (FEV1), unit L | Up to 52 weeks | |
| Secondary | Change from baseline in ACQ-6 | Asthma Control Questionnaire (6-item version) (ACQ-6 )
The 6 items in ACQ-6 have a 7-point scale ranging from 0=no impairment to 6=maximum impairment. The ACQ-6 score is calculated by taking the mean of the 6 equally weighted items ranging from 0=well controlled to 6=extremely poorly controlled. Higher scores indicate worse disease control. |
Up to 52 weeks | |
| Secondary | Change from baseline in sino-nasal symptoms (SSQ) | Sino-nasal Symptoms Questionnaire (SSQ)
SSQ captures 5 different sino-nasal symptoms over the previous week as scored as none, mild, moderate, severe, or very severe. Higher scores indicate greater severity. |
Up to 52 weeks | |
| Secondary | Change from baseline in SNOT-22 | Sino-nasal Outcome Test-22 (SNOT-22)
The 22 items in SNOT-22 have a 6-point scale ranging from 0=no problem to 5=problem as bad as it can be. The total score is the sum of item scores and has a range from 0 to 110. Higher scores indicate poorer outcomes. |
Up to 52 weeks | |
| Secondary | Change from baseline in SF-36v2 | Short Form 36-item health survey (version 2, acute recall) (SF-36v2)
The short form 36-item health survey, version 2 (SF-36v2) is a 36-item, self-report survey of functional health and well-being. The assessment yields 8-domain profile consisting of the following: Physical functioning (PF), role limitations due to physical health (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) are computed from subscale scores to give a broader metric of physical and mental health-related quality of life. The score range is 0 to 100 with higher scores indicating better health status. |
Up to 52 weeks | |
| Secondary | Change from baseline in PGIS | Patient Global Impression of Severity (PGIS)
PGIS is a 6-point categorical response scale ranging from 0=no symptoms to 6= very severe symptoms. Higher scores indicate worse severity. |
Up to 52 weeks | |
| Secondary | Change from baseline in WPAI | Work productivity and Activity Impairment Questionnaire (WPAI)
WPAI consists of 6 questions regarding absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment. WPAI outcomes are scored as impairment percentages, with a higher percentage indicating greater impairment and less productivity. |
Up to 52 weeks | |
| Secondary | Change from baseline in blood eosinophil counts | Up to 52 weeks | ||
| Secondary | Proportion of PGIC responders at each weekly assessment | Patient Global Impression of Change (PGIC)
Patient Global Impression of Change (PGIC) measures the patient´s overall impression of response to treatment since the initial dose using a 7-point scale ranging from "much better", "about the same" to "much worse". Lower scores indicate better health status. |
Up to 4 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03410290 -
Journey of Patients With Vasculitis From First Symptom to Diagnosis
|